

COMMENTARY

Open Access

Acute kidney injury in SARS-CoV-2 infected patients



Vito Fanelli¹, Marco Fiorentino², Vincenzo Cantaluppi³, Loreto Gesualdo⁴, Giovanni Stallone⁵, Claudio Ronco⁶ and Giuseppe Castellano^{5*}

Background

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the pathogen responsible of atypical pneumonia that has affected more than 330,000 people and caused death of more than 14,000 patients (as of March 23, 2020, WHO Report). Coronavirus spike (S) glycoproteins mediate entry into cells end predominantly lung epithelial alveolar cells precipitating an interstitial pneumonia that evolves through acute respiratory distress syndrome (ARDS) [1]. Interestingly, about 25% of acute kidney injury (AKI) occurrence has been reported in this clinical setting [2, 3]. These data were recently confirmed by the Italian Report of “Istituto Superiore di Sanità” describing an incidence of 27.8% in more than 2000 patients (updated on 17 March) (https://www.epicentro.iss.it/coronavirus/bollettino/Report-COVID-2019_17_marzo-v2.pdf).

In this commentary, we discuss possible mechanisms of the COVID-19-induced AKI, indicating potential new approaches for risk stratification of SARS-CoV-2 infected patients that may help clinical decision in this emerging scenario.

Main text

AKI represents a life-threatening complication in critically ill patients, often leading to increased risk of death. As recently reported by Wilson et al., the onset of moderate-to-severe AKI described a higher-risk subset of ARDS patients, with a significant risk for mortality [4]. Considering the possible pathogenic mechanisms of AKI-associated ARDS, AKI may be ascribed to different causes such as impairment of gas exchange, hemodynamic alterations including right heart failure,

fluid overload and systemic congestion, injurious mechanical ventilation strategies, and development of secondary infections/sepsis. Several studies emphasized the relevance of the inflammatory/immune-mediated reaction with the release of high levels of circulating harmful mediators capable to interact with kidney-resident cells causing endothelial dysfunction, microcirculatory derangement, and tubular injury [5]. In accordance with previous studies, the beta coronaviruses SARS-CoV and the most recent SARS-CoV-2 use angiotensin-converting enzyme 2 (ACE-2) as receptor to facilitate viral entry into target cells; ACE-2 is also located on the surface of kidney tubular cells, and their infection may worsen the local inflammatory response and consequently the incidence and the duration of AKI episodes [6] (Table 1).

As described, AKI developed in average 9 days after admission together with secondary infections and acute cardiac damage [2, 3]. Age, severity of illness, and the presence of diabetes are risk factors for AKI in ARDS patients; moreover, the severity of AKI is further associated with BMI and history of heart failure also defined as cardio-renal syndrome [7]. Similar observations, including the presence of diabetes, have been reported for COVID-19-associated ARDS. All these risk factors added to the increased incidence of AKI in elderly lead to the hypothesis that renal complications are predominant in patients with pre-existing chronic impairment of kidney function that is difficult to evaluate based only on serum creatinine levels, thus claiming for the use of new biomarkers of early kidney injury.

Therefore, determining the risk for developing AKI in SARS-CoV-2 infected patients or progressing to severe AKI requiring renal replacement therapies [8] is an important step for the patient's prognosis and for early implementation of preventative and protective measures [7,

* Correspondence: giuseppe.castellano@unifg.it

⁵Nephrology, Dialysis and Transplantation Unit, Department of Medical and Surgical Science, University of Foggia, Foggia, Italy

Full list of author information is available at the end of the article



© The Author(s). 2020 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Table 1 Key points of acute kidney injury in SARS-CoV-2 infected patients

- AKI is frequently observed in ARDS patients affected by different comorbidities: similar findings were observed in Wuhan COVID-19 infected patients.
- ARDS-associated AKI may be ascribed to several causes including an inflammatory/immune reaction characterized by an enhanced release of circulating mediators able to interact and damage kidney-resident cells.
- Kidney epithelial cell viral infection may worsen local inflammatory response and consequently the incidence and the duration of AKI episodes.
- These comorbidities may be associated with a pre-existing chronic decline of kidney function (concept of renal functional reserve) and with a tendency to develop AKI episodes.
- Identification of patients with AKI may lead to a better allocation of hospital resources: early biomarkers of AKI may favor this process.
- The use of extracorporeal blood purification techniques and anti-viral therapies may theoretically limit the systemic and local inflammatory response at least in part responsible for multiple organ failures including AKI.

9]. Classical assessment of AKI is still based on serum creatinine and urine output, but they represent only indicators of established kidney damage. In this scenario, much attention has focused on novel biomarkers in the last years, particularly on markers of acute tubular stress/damage such as TIMP-2 (tissue inhibitor of metalloproteinase 2) and IGFBP7 (insulin-like growth factor binding protein 7) and their product [TIMP-2]*[IGFBP-7] identified using the NephroCheck Test [10]. This test has been set for the prediction of moderate to severe AKI within 12 h after ICU admission, and it is the only one approved by the Food and Drug Administration in this setting [11]. Several evidences suggested that the application of NephroCheck may help physicians to identify patients with tubular stress, before kidney dysfunction is manifested [12]. Critically ill patients are indeed exposed to several potential kidney insults in this setting (SARS-CoV-2 infection, drug nephrotoxicity, contrast media) during ICU stay; serial measurements of these biomarkers may be a useful tool to predict AKI during the first 7 days of ICU stay [13].

A positive test suggesting a high risk of developing AKI may require an early nephrology consultation [7], the close monitoring of creatinine and urine output, the optimization of volume and hemodynamic status, the avoidance of iodinated contrast procedures when possible and the use of nephrotoxic drugs (e.g., aminoglycosides, ACE inhibitors, NSAIDs), or the close monitoring of drug levels (vancomycin) [7–14].

Conclusions

ARDS patients developing AKI are a higher risk for severe outcomes and mortality. In our opinion, it is

compelling to establish a prediction model to stratify SARS-CoV-2 infected patients according to AKI severity; this approach might lead to an innovative biomarker-based interventional strategy in this emerging clinical contest leading to a better allocation of hospital resources.

Acknowledgements

Not applicable

Authors' contributions

VF and GC contributed to the conception and the design of the article. VF, MF, and VC participated in reviewing the literature bibliography search and writing of the paper. GS, LG, CR, and GC provided critical review and revised the paper. All authors gave final approval for the present version to be submitted.

Funding

No funding

Availability of data and materials

Not applicable

Ethics approval and consent to participate

Not applicable

Consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests.

Author details

¹Department of Surgical Science, Division of Anesthesia and Critical Care Medicine, University of Turin, AOU Città della Salute e della Scienza di Torino, Turin, Italy. ²Nephrology Unit, "Mons. Dimiccoli" Hospital Barletta, Barletta, Italy. ³Nephrology and Kidney Transplantation Unit, Department of Translational Medicine and Center for Autoimmune and Allergic Diseases (CAAD), University of Piemonte Orientale (UPO), "Maggiore della Carità" University Hospital, Novara, Italy. ⁴Nephrology, Dialysis and Transplantation Unit, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy. ⁵Nephrology, Dialysis and Transplantation Unit, Department of Medical and Surgical Science, University of Foggia, Foggia, Italy. ⁶Department of Nephrology Dialysis and Transplantation, International Renal Research Institute of Vicenza, San Bortolo Hospital, Vicenza, Italy.

Received: 24 March 2020 Accepted: 3 April 2020

Published online: 16 April 2020

References

1. Ranieri VM, Rubenfeld GD, et al. Acute respiratory distress syndrome: the Berlin definition. *JAMA*. 2012;307(23):2526–33. <https://doi.org/10.1001/jama.2012.5669>.
2. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centred, retrospective, observational study. *Lancet Respir Med* 2020; published online Feb 21. doi: [https://doi.org/10.1016/S2213-2600\(20\)30079-5](https://doi.org/10.1016/S2213-2600(20)30079-5).
3. Fei Zhou, Ting Yu, Ronghui Du et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020; published Online March 9 doi: [https://doi.org/10.1016/S0140-6736\(20\)30566-3](https://doi.org/10.1016/S0140-6736(20)30566-3).
4. Wilson JG, Calfee CS. ARDS subphenotypes: understanding a heterogeneous syndrome. *Crit Care*. 2020;24:102. <https://doi.org/10.1186/s13054-020-2778-x>.
5. Joannidis M, Forni LG, Klein SJ, et al. Lung-kidney interactions in critically ill patients: consensus report of the Acute Disease Quality Initiative (ADQI) 21 Workgroup. *Intensive Care Med*. 2019. <https://doi.org/10.1007/s00134-019-05869-7>.
6. Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. *Nat Microbiol*. 2020. <https://doi.org/10.1038/s41564-020-0688-y>.

7. KDIGO Clinical Practice Guideline for Acute Kidney Injury. *Kidney Int Suppl* 2011; 2(1):2. doi:<https://doi.org/10.1038/kisup.2012.2>.
8. Ronco C, Navalesi P, Vincent JL. Coronavirus epidemic: preparing for extracorporeal organ support in intensive care. *Lancet Respir Med* 2020; 8(3): 240–241. doi: [https://doi.org/10.1016/S2213-2600\(20\)30060-6](https://doi.org/10.1016/S2213-2600(20)30060-6). Epub 2020 Feb 6.
9. Kellum JA, Prowle JR. Paradigms of acute kidney injury in the intensive care setting. *Nat Rev Nephrol*. 2018. <https://doi.org/10.1038/nrneph.2017.184>.
10. Pike F, Murugan R, Keener C, et al. Biomarker enhanced risk prediction for adverse outcomes in critically ill patients receiving RRT. *Clin J Am Soc Nephrol*. 2015;10:1332–9.
11. Kashani K, Al-Khafaji A, Ardiles T, et al. Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. *Crit Care*. 2013;17(1):R25. <https://doi.org/10.1186/cc12503>.
12. Bihorac A, Chawla LS, Shaw AD, et al. Validation of cell-cycle arrest biomarkers for acute kidney injury using clinical adjudication. *Am J Respir Crit Care Med*. 2014;189:932–9.
13. McCullough PA, Ostermann M, Forni LG, et al. Serial urinary tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 and the prognosis for acute kidney injury over the course of critical illness. *Cardiorenal Med*. 2019;9(6):358–69. <https://doi.org/10.1159/000502837>.
14. Vijayan A, Faubel S, Askenazi DJ, et al. Clinical use of the urine biomarker [TIMP-2] x [IGFBP7] for acute kidney injury risk assessment. *Am J Kidney Dis*. 2016;68:19–28.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.